Business

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabio

articleBeta Bionics, Inc.February 19, 20261/company/beta-bionics-inc-common-stock/news/beta-bionics-to-present-at-the-td-cowen-46th-annual-health-care-conference
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

About this update from Beta Bionics, Inc.

[{"type":"image","alt":"Beta Bionics, Inc.","displaySize":"","headline":null,"caption":"Beta Bionics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/0d351b90d528509a207c521057a3f8fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/opKmW85NqbPOJmMm79loLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0d351b90d528509a207c521057a3f8fc","width":300,"height":51}},"lazy":false},{"type":"text","content":"IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time).","length":337,"tagName":"p"},{"type":"text","content":"A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the event.","length":241,"tagName":"p"},{"type":"text","content":"About Beta Bionics","length":18,"tagName":"p"},{"type":"text","content":"Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.","length":609,"tagName":"p"},{"type":"text","content":"Investor Relations:Blake BeberHead of Investor [email protected]","length":77,"tagName":"p"},{"type":"text","content":"Media and Public Relations: Karen HynesVice President of [email protected]","length":90,"tagName":"p"},{"type":"text","content":"Source: Beta Bionics, Inc.","length":31,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]

More updates from Beta Bionics, Inc.

Annual Health Care Conferencediabetes managementGLOBE NEWSWIREBionics